Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Market Research - Acceptability Study for a New PKU Glycomacropeptide Based Protein Substitute (Dr Schär- Mevalia Amino Acids) Mevalia PKU GMPower - Vanilla

NCT04318509 is registered in ClinicalTrials.gov with Dr. Schär AG / SPA as lead sponsor.

NCT NCT04318509
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04318509 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Market Research - Acceptability Study for a New PKU Glycomacropeptide Based Protein Substitute (Dr Schär- Mevalia Amino Acids) Mevalia PKU GMPower - Vanilla
Lead sponsor
Dr. Schär AG / SPA
Phase
Not applicable
Overall status
Completed
Start date
February 4, 2019
Completion date
May 19, 2019
Enrollment
8 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

inborn errors of metabolism, metabolic disease, phenylketonurias, pku